ES2080341T3 - Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral. - Google Patents

Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.

Info

Publication number
ES2080341T3
ES2080341T3 ES91918778T ES91918778T ES2080341T3 ES 2080341 T3 ES2080341 T3 ES 2080341T3 ES 91918778 T ES91918778 T ES 91918778T ES 91918778 T ES91918778 T ES 91918778T ES 2080341 T3 ES2080341 T3 ES 2080341T3
Authority
ES
Spain
Prior art keywords
polypeptide
gene encoding
promoter
exogenous gene
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918778T
Other languages
English (en)
Inventor
Philip Frost
Bert Vogelstein
Yuti Chernajovsky
Eric R Fearon
Drew Pardoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Texas System
University of Texas at Austin
Original Assignee
Johns Hopkins University
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24330225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2080341(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University, University of Texas System, University of Texas at Austin filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2080341T3 publication Critical patent/ES2080341T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA PREPARACION DE LINEAS DE CELULAS TUMORALES QUE CONTIENEN UN GEN EXOGENO QUE CODIFICA UN POLIPEPTIDO QUE POTENCIA LA RESPUESTA INMUNE AL TUMOR, P.E., INTERLEUQUIN-2. LA INVENCION INCLUYE METODOS PARA TERAPIA DEL CANCER MEDIANTE LA INMUNIZACION CON LA CELULA TUMORAL INMUNOPOTENCIADORA. LA INVENCION PROPORCIONA TAMBIEN METODOLOGIA MEDIANTE LA CUAL SE PUEDE EXTIRPAR IN VITRO E IN VIVO CELULAS GENETICAMENTE ALTERADAS. UNA REALIZACION PREFERIDA DE ESTE ASPECTO DE LA INVENCION INCLUYE UNA CELULA QUE CONTIENE UN PRIMER GEN EXOGENO QUE CODIFICA UN POLIPEPTIDO INMUNOPOTENCIADOR Y UN SEGUNDO GEN EXOGENO QUE CODIFICA UN POLIPEPTIDO "LETAL" O "SUICIDA", PREFERIBLEMENTE BAJO EL CONTROL DE UN PROMOTOR INDUCIDO. LA INTRODUCCION DEL SEGUNDO GEN EXOGENO CONFIERE LA CAPACIDAD PARA EXTIRPAR SELECTIVAMENTE LA CELULA TUMORAL INDUCIENDO UN PROMOTOR EN ENLACE OPERATIVO CON EL GEN QUE CODIFICA EL POLIPEPTIDO LETAL PARA INICIAR LA TRANSCRIPCION DEL POLIPEPTIDO. LA TOXINA DE DIFTERIA O LA QUINASA DE TIMIDINA DEL VIRUS DEL HERPES SIMPLE SON GENES LETALES EJEMPLARES. UN PROMOTOR EJEMPLAR UTILIZADO ES EL PROMOTOR 6-16, QUE ES INDUCIBLE CON BAJOS NIVELES DE INTERFERON. ASIMISMO, LA INVENCION SE REFIERE A METODOS PARA UTILIZAR CELULAS EN LA TERAPIA DEL CANCER.
ES91918778T 1990-09-14 1991-09-12 Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral. Expired - Lifetime ES2080341T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58271190A 1990-09-14 1990-09-14

Publications (1)

Publication Number Publication Date
ES2080341T3 true ES2080341T3 (es) 1996-02-01

Family

ID=24330225

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918778T Expired - Lifetime ES2080341T3 (es) 1990-09-14 1991-09-12 Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.

Country Status (10)

Country Link
EP (1) EP0551401B2 (es)
JP (3) JPH06501161A (es)
AT (1) ATE129746T1 (es)
AU (1) AU3041295A (es)
CA (1) CA2091346C (es)
DE (1) DE69114299T3 (es)
DK (1) DK0551401T3 (es)
ES (1) ES2080341T3 (es)
GR (1) GR3018897T3 (es)
WO (1) WO1992005262A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
CA2113990A1 (en) * 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IL99821A (en) * 1991-10-22 1996-07-23 Yeda Res & Dev Antitumor vaccines comprising cells transfected with a gene encoding human il-6
ES2144426T3 (es) * 1991-10-25 2000-06-16 Sidney Kimmel Cancer Ct Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
WO1993021959A1 (en) * 1992-05-01 1993-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bystander effect tumoricidal therapy
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
DE69433110T2 (de) * 1993-02-17 2004-06-03 Sloan-Kettering Institute For Cancer Research Allogenes vakzin und synthesemethode für selbiges
AU729199B2 (en) * 1993-02-22 2001-01-25 Assistance Publique - Hopitaux De Paris Composition for use in the treatment of tumours and the immunization of humans and animals
FR2699082B1 (fr) * 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
IT1261847B (it) * 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
EP0722343A4 (en) * 1993-10-06 1999-12-29 Us Gov Health & Human Serv TREATMENT OF TUMORS BY GENETIC TRANSFORMING TUMOR CELLS WITH GENES ENCODING SELECTIVE, NEGATIVE MARKERS AND CYTOKINS
FR2712602B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
WO1995031105A1 (en) * 1994-05-13 1995-11-23 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants
WO1995031208A1 (en) * 1994-05-16 1995-11-23 Boehringer Mannheim Gmbh Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic t-cells
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
DE69531387T2 (de) * 1994-08-16 2004-04-22 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
DE19510344C1 (de) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Verwendung einer Tumorvakzine
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
JP2000502711A (ja) * 1995-12-28 2000-03-07 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オブ メディシン 同種異系パラクリンサイトカイン腫瘍ワクチン
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6268214B1 (en) 1996-04-04 2001-07-31 Roche Diagnostics Gmbh Vectors encoding a modified low affinity nerve growth factor receptor
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
ATE283069T1 (de) 1996-08-16 2004-12-15 Univ Johns Hopkins Med Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
US9907582B1 (en) 2011-04-25 2018-03-06 Nuvasive, Inc. Minimally invasive spinal fixation system and related methods
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity

Also Published As

Publication number Publication date
AU3041295A (en) 1995-11-09
JP2009165490A (ja) 2009-07-30
DE69114299T2 (de) 1996-06-27
WO1992005262A1 (en) 1992-04-02
CA2091346C (en) 2007-04-24
JPH06501161A (ja) 1994-02-10
JP2007277265A (ja) 2007-10-25
DE69114299T3 (de) 2005-09-15
GR3018897T3 (en) 1996-05-31
EP0551401A1 (en) 1993-07-21
EP0551401B1 (en) 1995-11-02
CA2091346A1 (en) 1992-03-15
DE69114299D1 (de) 1995-12-07
EP0551401B2 (en) 2004-12-01
ATE129746T1 (de) 1995-11-15
DK0551401T3 (da) 1996-01-22
AU8764391A (en) 1992-04-15
AU659812B2 (en) 1995-06-01

Similar Documents

Publication Publication Date Title
ES2080341T3 (es) Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
EP1648931B1 (en) Multifunctional cytokines
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
AU7599500A (en) Novel gl50 molecules and uses therefor
DK0707071T3 (da) Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
DK305885A (da) Tumornecrosefaktor og derivater og mutantformer deraf, frem. til frems. deraf, frem. til isolering deraf fra en blanding med andre proteiner,praeparater deraf, dna som koder derfor, dna'en inkorporeret i en replicerbar vektor og celle transformeret dermed
WO2003023000A3 (en) Linear dna fragments for gene expression
EE200300332A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
JP2001508304A (ja) 細胞内及び細胞間輸送のための融合タンパク質、並びにその使用
AU2009222623A1 (en) Novel multifunctional cytokines
EA002688B1 (ru) Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов
WO2003042362A8 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
KR970705416A (ko) 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases)
CN119040361A (zh) 核酸构建体
Delman et al. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer
KR970706397A (ko) IV a2 유전자가 불활성화된 결손 재조합 아데노바이러스(DEFECTIVE RECOMBINANT ADENOVIRUSES WITH AN INACTIVATED IV a2 GENE)
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
Isenmann et al. Intravitreal adenoviral gene transfer evokes an immune response in the retina that is directed against the heterologous lacZ transgene product but does not limit transgene expression
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
Yeung et al. Production of rabbit polyclonal antibody against apobec-1 by genetic immunization
KR100399728B1 (ko) ＩＬ-12 활성을 증가시키는 ＩＬ-12ｐ40 소단위체돌연변이 유전자 및 이를 ＤＮＡ 백신 면역증강제로이용하는 용도
WO2001068857A3 (en) 18615 and 48003, human ion channels and uses therefor
WO2002010391A3 (en) 18610, a human transient receptor and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 551401

Country of ref document: ES